At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 947 enrolled
Drug / intervention
Fesoterodine +1 moredrug
Likely dose
Fesoterodine 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Fesoterodine As An "Add-On" Therapy In Men With Persistent Overactive Bladder Symptoms Under Monotherapy Of Alpha Blocker For Lower Urinary Tract Symptoms.
In Brief
A Phase 3 clinical trial evaluating Fesoterodine and Placebo for Overactive Bladder Syndrome. Completed, enrolled 947 participants across 137 sites in 19 countries.
Detailed Summary
To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder Syndrome
CountriesBelgium, Brazil, Canada, Colombia, Germany, Greece, India, Malaysia, Netherlands, Norway, Philippines, Poland, Singapore, Slovakia, South Korea, Spain, Sweden, Thailand, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2007
Enrollment StartNov 2007
Primary CompletionFeb 2009
TodayJul 2026
First PostedOct 19, 2007
Enrollment StartNov 1, 2007
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.7 years ago
Interventions
Fesoterodinedrug
Fesoterodine 4mg or 8mg
Placebodrug
Placebo